N
anotechnology has been exploited extensively to enhance the pharmacokinetic properties and therapeutic index of a myriad of drugs. 1Ϫ4 In the past two decades, a large number of nanoparticle-based therapeutic products have entered clinical development or been approved for clinical use. 5 Polymeric nanoparticles (NPs) and liposomes represent two dominant classes of nanocarriers capable of efficiently encapsulating and delivering a variety of drug classes. 5, 6 Polymeric NPs which are suitable for systemic administration may be formed by self-assembly of biodegradable copolymers consisting of two or more polymer blocks with different hydrophobicities. The use of amphiphilic polymers results in formation of NPs with a hydrophobic core and a hydrophilic shell. The coreϪshell structure of polymeric NPs allows them to encapsulate and carry poorly water-soluble drugs, decrease the biofouling of the NPs resulting in long circulation half-life, release drugs at a sustained rate in the optimal range of drug concentration, and be further functionalized with targeting ligands for differential delivery. 7Ϫ9 In addition, the preparation of polymeric NPs based on the nanoprecipitation or double emulsion methods is simple and scalable. 7 For example, Genexol-PM is a NP formulation of paclitaxel and poly(D,L-lactide)-bpolyethylene glycol-methoxy, which has been approved for metastatic breast cancer therapy in Korea. 10 Liposomes are spherical lipid vesicles with a bilayer structure of natural or synthetic amphiphilic lipid molecules. Liposomes have been widely used as drug delivery vehicles because of favorable safety profile, ease of surface modification, and long systemic circulation halflife that can reach days after being surface modified with hydrophilic polymers such as polyethylene glycol (PEG). 11, 12 Several liposomal drug formulations have been approved for clinical use, including Doxil (doxorubicin liposomes) 13 which was first to be approved in 1995, AmBisome (amphotericin B liposomes), DaunoXome (daunorubicin liposomes), DepoCyt (cytarabine liposomes), DepoDur (morphine liposomes), and Visudyne (verteporfin liposomes). 5, 12 Given the clinical success of polymeric NPs and liposomes, we hypothesized that a lipidϪpolymer hybrid NP may be developed that takes advantage of the unique strengths of polymeric NPs and liposomes. The hybrid NPs can be a robust drug delivery platform with high drug encapsulation yield, tunable and sustained drug release profile, excellent serum stability, and potential for differential targeting of cells or tissues. Previously, polymeric NPs were mixed with liposomes to form lipidϪpolymer complexes such as lipoparticles where the lipid *Address correspondence to ofarokhzad@zeus.bwh.harvard.edu.
bilayer or lipid multilayer fuses on the surface of polymeric NPs.
14Ϫ16 These complexes usually require a twostep formulation process: (i) development of polymeric NPs, and (ii) encapsulation of polymeric NPs within liposomes, resulting in a poor control over the final NP physicochemical structure which may hinder their clinical translation. It is desirable to develop lipidϪpolymer hybrid NPs using a well-defined and predictable formulation strategy in a single step, which may facilitate future scale-up.
Here we report a platform to engineer sub-100 nm targeted lipidϪpolymer hybrid NPs through a combination of nanoprecipiation and self-assembly. These NPs combine the desirable characteristics of polymeric NPs and liposomes, while excluding some of their intrinsic limitations. The NPs comprise three distinct functional components: (i) a biodegradable hydrophobic polymeric core that can carry poorly water-soluble bioactive drugs and release them at a sustained rate; (ii) a stealth material forming a hydrophilic shell that can allow the particles to evade recognition by immune system components and increase particle systemic circulation half-life; and (iii) a lipid monolayer at the interface of the hydrophobic core and the hydrophilic shell, which can prevent the carried agents from freely diffusing out of the NPs and reduce water penetration rate into the NPs, thereby enhancing drug encapsulation yield and slowing drug release from the NPs. For targeted delivery purposes, the surface of NPs can be functionalized with targeting molecules that can bind to unique molecular signatures on cells or tissues of interest.
RESULTS AND DISCUSSION
In this study, we used ester-terminated poly D,Llactic-co-glycolic acid (PLGA) as a model hydrophobic polymer to form the polymeric core of the NPs; polyethylene glycol (PEG), which is covalently conjugated to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), as a model hydrophilic polymer to form the "stealth" shell of the NPs; and lecithin as a model lipid to form the lipid monolayer at the interface of the PLGA core and PEG shell. Since both PLGA and DSPEϪPEG polymers have been approved by the Food and Drug Administration (FDA) for medical applications and lecithin is a natural lipid extracted from soybean, we expect the lipidϪpolymer hybrid NPs should be biocompatible, biodegradable, and potentially safe as a drug carrier for clinical use. As illustrated in Figure 1A , the lipidϪpolymer hybrid NPs are self-assembled from PLGA, lecithin, and DSPEϪPEG conjugate through a single-step nanoprecipitation method. Specifically, PLGA polymer precipitates to form a hydrophobic core to encapsulate poorly water-soluble drugs. Lecithin and DSPEϪPEG conjugates self-assemble around the PLGA core to form a lipid monolayer covered by a PEG shell.
To characterize the structure of the NPs, they were imaged by transmission electron microscopy (TEM) with negative staining by uranyl acetate which stains lecithin and the lipids conjugated with PEG to enhance their electron density, resulting in a dim ring surrounding the PLGA core ( Figure 1B ). The thickness of the ring is less than 5 nm, which equals the thickness of a lecithin monolayer plus a PEG shell. The lipid/polymer weight ratio and PLGA molecular weight may be changed to fine-tune NP size (diameter, nm) and surface charge ( potential, mV), to achieve the optimal NP pharmacokinetic properties in vivo. As shown in Figure 1C , the lipid/ polymer weight ratio of 10Ϫ20% results in NPs with favorable combination of size (70Ϫ80 nm) and potential (Ϫ30 to Ϫ35 mV) for drug delivery application. 17 One possible explanation is that, at this ratio, the amount of lipids is in the range to cover the entire surface of the PLGA hydrophobic core. However, when the ratio of lipid to polymer is too high, the excess lipids may increase above the critical micellar concentration (CMC) of lecithin (ϳ0.4 mg/mL, data from manufacturer), resulting in the assembly of lecithin liposomes (typical size is about 100Ϫ1000 nm). The coexistence of these liposomes would enhance the overall measured size of the hybrid NPs and lower their potential value. Conversely, when the lipid/polymer weight ratio is too low, there is a paucity of lipids to cover the surface of the PLGA core, resulting in a high potential value (close to bare PLGA NPs). In the following studies, we formulated lipidϪpolymer hybrid NPs (1 mg/mL) using a lipid/polymer weight ratio of 15% translating to a starting lipid concentration of 0.15 mg/mL, which is lower than the CMC of lecithin. Dynamic light scattering measurements further demonstrated that liposomes are not formed at the low concentration of lecithin used in our protocol. By keeping the lipid/polymer weight ratio constant at 15%, we varied the PLGA inherent viscosity and demonstrated that we can fine-tune NP size in a highly reproducible manner while minimally affecting NP surface charge. For example, when the inherent vis- www.acsnano.org cosity of PLGA was increased from 0.19 to 0.82, the NP size dropped from 92.7 Ϯ 2.0 nm (polydispersity ϭ 0.211 Ϯ 0.008, mean Ϯ SD, N ϭ 3) to 66.7 Ϯ 4.5 nm (polydispersity ϭ 0.244 Ϯ 0.005, mean Ϯ SD, N ϭ 3) ( Figure 1D ), while the NP potential only slightly fluctuated in the range of Ϫ30.2 to Ϫ34.3 mV. The observed effect of polymer inherent viscosity on NP size was quite consistent with what has been previously reported for PLGAϪPEG polymeric NPs. 18 A possible mechanism is that higher molecular weight polymers precipitate to form more compact structures during the process of nanoprecipitation as compared to equivalent polymers with a lower molecular weight.
Next, we examined drug encapsulation yield, loading yield, and release profile of the lipidϪpolymer hybrid NPs in comparison with PLGAϪPEG polymeric NPs and PLGA polymeric NPs. We hypothesized that the addition of a lipid monolayer at the interface of the PLGA core and the PEG shell may serve two distinct functions: (i) to prevent small drug molecules from freely diffusing out of the PLGA core, thereby improving drug encapsulation yield and loading yield, and (ii) to reduce the water penetration rate into the PLGA core, thereby decreasing the rate of hydrolysis of PLGA polymers resulting in slower drug release from the NPs. To test these hypotheses, docetaxel (Dtxl), a widely used anticancer drug, was selected as a model hydrophobic drug to be encapsulated in the lipidϪpolymer hybrid NPs. As shown in Figure 2A , when Dtxl was mixed with PLGA at the weight ratio of 5:100 and dissolved in acetonitrile for the preparation of lipidϪpolymer hybrid NPs, 59 Ϯ 4% (mean Ϯ SD, N ϭ 3) of Dtxl was encapsulated into the NPs. In contrast, Dtxl encapsulation yields of PLGAϪPEG NPs and PLGA NPs were approximately 19 Ϯ 3% (mean Ϯ SD, N ϭ 3) and 37 Ϯ 4% (mean Ϯ SD, N ϭ 3), respectively. The relatively low encapsulation yield of PLGAϪPEG NPs may stem from the possibility that some PEG blocks were buried inside PLGAϪPEG diblock copolymer NPs during a nanoprecipitation process which results in a less hydrophobic core than the pure PLGA polymeric core of both the lipidϪpolymer hybrid NPs and the PLGA NPs. In addition, the encapsulated Dtxl was released from the hybrid NPs at a sustained rate over 120 h ( Figure 2B ). When lipidϪpolymer hybrid NPs, PLGAϪPEG NPs, and PLGA NPs were each loaded with Dtxl at approximately 3 wt %, it took the hybrid NPs around 20 h to release 50% of Dtxl versus 10 and 7 h for PLGAϪPEG NPs and PLGA NPs, respectively. These results indicate that the lipid monolayer at the interface of the PLGA core and the PEG shell acts as a molecular fence that helps to retain the drugs inside the NPs. We further observed that the high Dtxl encapsulation yield and the sustained drug release characteristics of these hybrid NPs are retained across a broad range of Dtxl input during NP formulation. For example, when the initial Dtxl input was 5, 10, and 15% of the weight of the PLGA polymer, the measured loading yield reached 3.0, 6.1, and 8.5%, respectively, which corresponded to a nearly constant encapsulation yield of 60% ( Figure 2C ). However, Dtxl encapsulation yield dropped when the initial drug input was increased to 20%. We also found that Dtxl was released from the hybrid NPs at a sustained manner until its loading yield was higher than ϳ6% ( Figure 2D ). NP stability in serum is an important criterion for their utility as drug carriers in vivo. Using the change in NP size in the presence of plasma as a surrogate for protein adsorption and biofouling, we next studied the serum stability of lipidϪpolymer hybrid NPs. We incubated the lipidϪpolymer hybrid NPs with 10% bovine serum albumin (BSA) solution and 10% human plasma solution and monitored changes in NP size over time. As controls, PLGAϪPEG polymeric NPs and PLGA polymeric NPs were similarly tested in parallel. As shown in Figure 3A ,B, the hybrid NPs and the PLGAϪPEG NPs were stable in 10% BSA solution retaining their size of 90 Ϯ 2 nm (polydispersity ϭ 0.223 Ϯ 0.011, mean Ϯ SD, N ϭ 3), while a slight in- crease in size was observed in 10% plasma solution. In contrast, PLGA NPs had a dramatic size increase from 90 to 200Ϫ300 nm within 10 min of incubation in BSA or plasma. Consistent with previous reports, we observed that the presence of PEG prevented protein adsorption on the NP surface, and the resulting decrease in NP biofouling has previously been shown to prolong NP systemic circulation half-life. We next demonstrated the suitability of these lipidϪpolymer hybrid NPs for targeted delivery applications. To this end, we covalently conjugated amine terminated A10 RNA aptamers to carboxylfunctionalized lipidϪPEG conjugates using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS) activation chemistry and used these lipidϪPEGϪaptamer conjugates in the self-assembly of lipidϪpolymer hybrid NPs. The A10 aptamer is a nuclease-stabilized 2=-fluoropyrimidine RNA molecule with 57 base pairs which has shown high binding affinity to the prostate specific membrane antigen (PSMA) overexpressed by some prostate cancer (PCa) cell lines. 19 In the study, LNCaP prostate adenocarcinomas, which express the PSMA antigen on their plasma membrane, were chosen as the target cell line for in vitro testing; PC3 prostate adenocarcinomas, which do not express the PSMA antigen, were employed as a negative control. To visualize cell uptake of the NPs using fluorescence microscopy, a hydrophobic fluorescent probe, NBDcholesterol (22-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3␤-ol) (excitation/emission ϭ 460 nm/534 nm), was encapsulated inside the hybrid NPs. 20 Figure 4 showed that PSMA-targeted NBD-encapsulated hybrid NPs were differentially taken up by LNCaP cells which express the PSMA protein ( Figure  4A) but not PC3 cells which do not express the PSMA protein ( Figure 4C ). The small amount of NBD signal from PC3 cells may represent a portion of free NBD released from the NPs during the incubation time or alternatively may represent nonspecific uptake of particles by the PC3 cells. When PSMA aptamer was not used, negligible amount of nontargeted NPs were delivered to LNCaP ( Figure 4B ) and PC3 ( Figure 4D ) cells. A recent report from our laboratory demonstrated the advantages of forming targeted NPs in a single-step process using a mixture of PLGAϪPEG diblock copolymers and preformed PLGAϪPEGϪaptamer triblock copolymers. 18 In contrast to the conventional two-step process that PLGAϪPEG NPs were first prepared and then surface functionalized with aptamer, this single-step synthesis approach allows one to produce large-scale targeted NPs while minimizing production time and NP batch-to-batch variation. However, problems arise when generalizing this idea to protein-based targeting systems using antibodies or affibodies simply because proteins cannot tolerate the harsh reaction environment with PLGAϪPEG polymer in organic solvent. Speculatively, the lipidϪpolymer hybrid NPs presented in this paper may provide a way to solve this problem. One can conjugate protein-based targeting ligands with lipidϪPEG in an aqueous environment to form a lipidϪPEGϪligand triblock structure and then mix it with lipidϪPEG and other components to form a targeted lipidϪpolymer hybrid NP in a single-step nanoprecipitation process.
CONCLUSION
In summary, we have developed a lipidϪpolymer hybrid NP platform consisting of a hydrophobic polymeric core, a hydrophilic polymeric shell, and a lipid monolayer at the interface of the core and the shell. These lipidϪpolymer hybrid NPs combine the merits of the polymeric NPs and liposomes. It has been demonstrated that the hybrid NP has tunable size and surface charge, high drug loading yield, sustained drug release profile, favorable stability in serum, good cellular targeting ability, and its simple synthesis process may www.acsnano.org be amenable to further scale-up if desired. All these positive attributes make the lipidϪpolymer hybrid NPs a promising drug delivery vehicle for further in vivo evaluation.
METHODS

NP Preparation:
LipidϪpolymer hybrid NPs were prepared via self-assembly of PLGA (poly(D,L-lactic-co-glycolic acid); Lactel, Pelham, AL), lecithin (soybean, refined, molecular weight: ϳ330 Da; Alfa Aesar, Ward Hill, MA), and DSPEϪPEG (1,2-distearoyl-snglycero-3-phosphoethanolamine-N-carboxy(polyethylene glycol)2000); Avanti, Alabaster, AL) through a single-step nanoprecipitation method. Briefly, PLGA polymer was dissolved in acetonitrile with concentrations ranging from 1 to 5 mg/mL. Lecithin/ DSPEϪPEG (8.5/1.5, molar ratio) with a weight ratio of 15% to the PLGA polymer was dissolved in 4 wt % ethanol aqueous solution. The lecithin/DSPEϪPEG solution was heated to 65°C to ensure all lipids were in liquid phase. The resulting PLGA solution was then added into the preheated lipid solution dropwise under gentle stirring. The mixed solution was vortexed vigorously for 3 min followed by gentle stirring for 2 h at room temperature. The remaining organic solvent and free molecules were removed by washing the NP solution three times using an Amicon Ultra-4 centrifugal filter (Millipore, Billerica, MA) with a molecular weight cutoff of 10 000 Da. To prepare drug-encapsulated NPs, docetaxel (Sigma-Aldrich, St Louis, MO) with proper initial dosage was dissolved into the PLGA acetonitrile solution before the nanoprecipitation process. NP size (diameter, nm) and surface charge ( potential, mV) were obtained from three repeat measurements by quasi-elastic laser light scattering with a ZetaPALS dynamic light scattering detector (15 mW laser, incident beam ϭ 676 nm; Brookhaven Instruments Corporation, Holtsville, NY).
Drug Loading and Release Study: To measure the drug loading yield and release profile of docetaxel (Dtxl) from each type of NPs, 3 mL of NP PBS solutions at a concentration of 5 mg/mL were split equally into 30 Slide-A-Lyzer MINI dialysis microtubes with a molecular weight cutoff of 3500 Da (Pierce, Rockford, IL). These microtubes were dialyzed in 4 L of PBS buffer at 37°C with gentle stirring. PBS buffer was changed every 24 h during the whole dialysis process. At each data point, NP solutions from three microtubes were collected separately and mixed with an equal volume of acetonitrile to dissolve the NPs. The resulting free Dtxl content in each microtube was assayed using an Agilent (Palo Alto, CA) 1100 HPLC equipped with a pentafluorophenyl column (Curosil-PFP, 250 ϫ 4.6 mm, 5 ; Phenomenex, Torrance, CA). Dtxl absorbance was measured by a UVϪvis detector at 227 nm and a retention time of 12 min in 1 mL/min 50/50 acetonitrile/water mobile phase.
NP In Vitro Stability: NPs were incubated with 10 vol % BSA (bovine serum albumin; Sigma-Aldrich, St Louis, MO) solution and 10 vol % human plasma (BioChemMed, Winchester, VA) solutions, respectively, at 37°C under gentle stirring at a concentration of 1 mg/mL. At each time point, an aliquot of NP solutions was collected to measure NP size using quasi-elastic laser light scattering. The measurements were performed in triplicate at room temperature.
Fluorescence Microscopy: To visualize cellular uptake of aptamertargeted lipidϪpolymer hybrid NPs using fluorescence microscopy, a hydrophobic fluorescent dye, NBD-cholesterol (22-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3␤-ol; Invitrogen, Carlsbad, CA) was encapsulated inside the NPs. The fluorescence emission spectrum of NBD (excitation/emission ϭ 460 nm/534 nm) was detected in the green channel (490 nm/528 nm) of a Delta Vision RT deconvolution microscope. In the study, the prostate LNCaP and PC3 cell lines were grown in 8-well microscope chamber slides in RPMI-1640 and Ham's F-12K medium, respectively, both supplemented with 100 units/mL aqueous penicillin G, 100 g/mL streptomycin, and 10% FBS (fetal bovine serum) at concentrations to allow 70% confluence in 24 h (i.e., 40 000 cells per cm 2 ). On the day of experiments, cells were washed with prewarmed PBS buffer and incubated with prewarmed fresh media for 30 min before adding NPs with a final concentration of ϳ250 g/mL (N ϭ 4). Cells were incubated with the NPs for 2 h at 37°C, washed two times with PBS (300 L per well), fixed with 4% formaldehyde, and mounted with nonfluorescent mounting medium DAPI (Vector Laboratory, Inc. Burlingame, CA). The cells were then imaged using a Delta Vision RT deconvolution microscope.
